CEL-SCI Co. Forecasted to Post FY2022 Earnings of ($0.23) Per Share (NYSEAMERICAN:CVM)

CEL-SCI Co. (NYSEAMERICAN:CVM) – Stock analysts at Zacks Investment Research issued their FY2022 earnings per share (EPS) estimates for CEL-SCI in a research note issued on Tuesday, January 11th. Zacks Investment Research analyst J. Vandermosten anticipates that the company will post earnings per share of ($0.23) for the year. Zacks Investment Research also issued estimates for CEL-SCI’s FY2023 earnings at $0.91 EPS.

CEL-SCI (NYSEAMERICAN:CVM) last issued its quarterly earnings data on Wednesday, December 22nd. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.09).

Shares of CVM stock opened at $6.61 on Thursday. The stock has a market cap of $285.84 million, a price-to-earnings ratio of -7.11 and a beta of 2.06. CEL-SCI has a 1 year low of $6.00 and a 1 year high of $40.91. The company has a debt-to-equity ratio of 0.23, a quick ratio of 10.99 and a current ratio of 11.50.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. State Board of Administration of Florida Retirement System boosted its holdings in CEL-SCI by 8.5% in the 2nd quarter. State Board of Administration of Florida Retirement System now owns 15,941 shares of the company’s stock valued at $138,000 after purchasing an additional 1,253 shares in the last quarter. LPL Financial LLC lifted its position in shares of CEL-SCI by 9.4% during the 2nd quarter. LPL Financial LLC now owns 16,892 shares of the company’s stock valued at $147,000 after acquiring an additional 1,450 shares during the period. Credit Suisse AG lifted its position in shares of CEL-SCI by 7.2% during the 3rd quarter. Credit Suisse AG now owns 24,457 shares of the company’s stock valued at $270,000 after acquiring an additional 1,642 shares during the period. Charles Schwab Investment Management Inc. lifted its position in shares of CEL-SCI by 2.2% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 91,713 shares of the company’s stock valued at $797,000 after acquiring an additional 1,996 shares during the period. Finally, Invesco Ltd. lifted its position in shares of CEL-SCI by 23.3% during the 3rd quarter. Invesco Ltd. now owns 16,261 shares of the company’s stock valued at $179,000 after acquiring an additional 3,068 shares during the period. 37.33% of the stock is currently owned by institutional investors.

In related news, insider Eyal Talor sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, October 19th. The stock was sold at an average price of $11.25, for a total transaction of $168,750.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 12.60% of the company’s stock.

CEL-SCI Company Profile

CEL-SCI Corp. is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers.

Further Reading: Total Return

Receive News & Ratings for CEL-SCI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CEL-SCI and related companies with MarketBeat.com's FREE daily email newsletter.